What is Saxenda® used for?
Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:
- ≥30 kg/m² (obese); or
- ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.1
Treatment with Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.1
This website offers some further information to help you better understand Saxenda®.
How Saxenda® works
Saxenda® contains the active substance liraglutide which works by acting on receptors in the brain that control appetite. The exact mechanism of action is not entirely clear.1
The clinical efficacy of Saxenda® has been assessed in a number of clinical trials.
Saxenda® safety information1,2
Since its introduction, over one million patients with obesity have been prescribed Saxenda®. As with all medications, Saxenda® may cause side effects, although not everyone will experience them.
Getting your patients started on Saxenda®
Saxenda® is a once-daily glucagon-like peptide-1 (GLP-1) analogue indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients.
Summary of Product Characteristics (SMPC)
For an overview of the Summary of Product Characteristics for Saxenda® click below.
For an overview of the Saxenda® Prescribing Information click below.
Reporting of side effects
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.
- Saxenda® Summary of Product Characteristics
- le Roux CW, Astrup A, Fujioka K,et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409